Pitolisant Granted Orphan Drug Status in Prader-Willi Syndrome
The FDA has granted Orphan Drug designation to Harmony Bioscience’s pitolisant for the treatment of Prader-Willi syndrome.
Stay updated with breaking news from Kumar Budur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted Orphan Drug designation to Harmony Bioscience’s pitolisant for the treatment of Prader-Willi syndrome.
Phase 2 study results reveal pitolisant significantly improved daytime sleepiness and fatigue in myotonic dystrophy type 1 patients.
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal...
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Good morning. My name is Ashley, and I’ll be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Third Quater 2023 Financial Results Conference Call. All participant lines have been placed on mute to […]